Probi
PROB | ST
Overview
Corporate Details
- ISIN(s):
- SE0001280355
- LEI:
- 5493004CJOCT273MU397
- Country:
- Sweden
- Address:
- Ideongatan 1A, 223 70 Lund
- Website:
- https://www.probi.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Probi is an international company focused exclusively on developing, producing, and delivering clinically proven probiotics. We’ve spent three decades exploring and refining solutions that make the health-enhancing benefits of probiotics available to people everywhere. We are experts at managing stable, live bacteria from R&D through every stage of the manufacturing process, and into finished products, including bulk formats, supplements, and functional foods. Health concepts, formulations, and formats are supported by documentation. Since our founding at Sweden’s Lund University, in 1991, Probi has expanded its presence to more than 40 markets. We hold more than 400 patents globally.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-02-03 09:20 |
Delisting Announcement
Avnotering av Probi
|
Swedish | 99.1 KB | |
| 2025-02-03 09:20 |
Delisting Announcement
Delisting of Probi
|
English | 103.2 KB | |
| 2025-01-22 15:55 |
Major Shareholding Notification
|
Swedish | 9.1 KB | |
| 2025-01-21 09:47 |
Major Shareholding Notification
|
Swedish | 8.9 KB | |
| 2025-01-20 22:01 |
Pre-Annual General Meeting Information
Notice of Extraordinary General Meeting in Probi AB (publ)
|
English | 123.5 KB | |
| 2025-01-20 22:01 |
Pre-Annual General Meeting Information
Kallelse till extra bolagsstämma i Probi AB (publ)
|
Swedish | 82.2 KB | |
| 2025-01-20 22:00 |
Delisting Announcement
Probi applies for delisting and convenes an Extraordinary General Meeting
|
English | 109.7 KB | |
| 2025-01-20 22:00 |
Delisting Announcement
Probi ansöker om avnotering och kallar till extra bolagsstämma
|
Swedish | 104.6 KB | |
| 2025-01-09 08:00 |
Report Publication Announcement
Probi senarelägger bokslutskommuniké för 2024
|
Swedish | 92.1 KB | |
| 2025-01-09 08:00 |
Report Publication Announcement
Probi postpones year-end report 2024
|
English | 81.1 KB | |
| 2024-12-13 17:18 |
M&A Activity
Statement from the independent bid committee of Probi in relation to the public…
|
English | 142.9 KB | |
| 2024-12-13 17:17 |
M&A Activity
Uttalande från den oberoende budkommittén i Probi med anledning av Symrise offe…
|
Swedish | 140.4 KB | |
| 2024-11-20 07:20 |
M&A Activity
Probi’s Board comments on Symrise’s public takeover offer
|
English | 101.9 KB | |
| 2024-11-20 07:19 |
M&A Activity
Probis styrelse kommenterar offentligt uppköpserbjudande från Symrise
|
Swedish | 104.9 KB | |
| 2024-07-16 08:00 |
Quarterly Report
|
Swedish | 727.9 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-01-30 | Jean-Yves Parisot | Other | Buy | 142,586 | 49,905,100.00 SEK |
| 2024-11-22 | Jean-Yves Parisot | Other | Buy | 42,076 | 14,726,600.00 SEK |
| 2024-11-21 | Jean-Yves Parisot | Other | Buy | 77,405 | 27,091,750.00 SEK |
| 2024-11-20 | Jean-Yves Parisot | Other | Buy | 169,053 | 59,168,550.00 SEK |
| 2022-05-06 | Henrik Lundkvist | Other | Buy | 100 | 27,981.00 SEK |
| 2022-04-29 | Tom Rönnlund | Other | Buy | 400 | 122,296.00 SEK |
| 2022-04-28 | Tom Rönnlund | Other | Buy | 955 | 287,015.70 SEK |
| 2020-05-06 | Tom Rönnlund | Other | Buy | 400 | 100,000.00 SEK |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Financière de Tubize S.A. | Belgium | TUBAT | |
|
Fine Foods & Pharmaceuticals Ntm | Italy | FF | |
|
Flerie AB | Sweden | FLERIE | |
|
Friulchem | Italy | FCM | |
|
FRP ADVISORY GROUP PLC | United Kingdom | FRP | |
|
Fuji Pharma Co.,Ltd. | Japan | 4554 | |
|
FunPep Company Limited | Japan | 4881 | |
|
Fuso Pharmaceutical Industries,Ltd. | Japan | 4538 | |
|
Galderma Group AG | Switzerland | GALD | |
|
GlaxoSmithKline PLC | United Kingdom | GSK |